AGO TUMOR - AN OVERVIEW

In summary, over the past decade quite possibly the most extraordinary gain has become realized in HER2/neu-overexpressing MBC. Introduction of bevacizumab to be a VEGF-directed specific treatment method stays an issue on discussion. Some of the novel therapeutics to the breast cancer armamentarium resulted in prolongation of survival for sufferers